XML 119 R69.htm IDEA: XBRL DOCUMENT v3.24.1
SHARE OPTION SCHEME (Tables)
 12 Months Ended
Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]  
Summary of Share Options Outstanding Under the Scheme The following share options were outstanding under the Scheme during the year:
202320222021
Weighted
average
exercise
price		Number of
options		Weighted
average
exercise
price		Number of
options		Weighted
average
exercise
price		Number of
options
US$ per share’000US$ per share’000US$ per share’000
At January 1,7.1370 9,1802.8970 9,5291.9353 14,241
Granted during the year23.5300 35519.4468 2,26515.4774 595
Forfeited during the year2.8336 (708)4.2888 (573)2.9987 (1,251)
Exercised during the year5.0687 (2,460)1.8032 (2,041)1.3346 (4,056)
At December 31,9.3287 6,3677.1370 9,1802.8970 9,529
Exercisable at December 314.5401 3,4702.8705 3,2811.4334 2,828
Summary of Exercise Prices and Exercise Periods of Share Options Outstanding
The exercise prices and exercise periods of the share options outstanding as at the end of the reporting period are as follows:
December 31, 2023
Number of
options ’000		Exercise price*
US$
per share		Exercise period
1,7470.5 2019/12/25 – 2027/12/25
8011.0 2019/07/01 – 2028/08/29
841.0 2019/12/31 – 2028/12/30
7231.5 2020/07/02 – 2029/07/01
15211.5 2020/11/29 – 2029/11/28
5411.5 2021/06/05 – 2030/06/04
25516.3 2021/09/01 – 2030/08/31
21014.1 2022/03/29 – 2031/03/28
16019.0 2022/08/27 – 2031/08/26
40918.4 2023/03/31 - 2032/03/30
74018.2 2023/04/30 - 2032/04/29
8018.4 2023/05/02 - 2032/05/01
4018.4 2023/05/05 - 2032/05/04
8018.4 2023/05/08 - 2032/05/07
20018.4 2023/05/10 - 2032/05/09
1019.7 2023/05/13 - 2032/05/12
20727.5 2023/06/30 - 2032/06/29
6023.3 2023/08/02 - 2032/08/01
35523.5 2024/04/03 - 2033/04/02
6,367
December 31, 2022
Number of
options ’000		Exercise price*
US$
per share		Exercise period
2,8750.5 2019/12/25 – 2027/12/25
1,2481.0 2019/07/01 – 2028/08/29
2711.0 2019/12/31 – 2028/12/30
1,3931.5 2020/07/02 – 2029/07/01
20111.5 2020/11/29 – 2029/11/28
9011.5 2021/06/05 – 2030/06/04
32216.3 2021/09/01 – 2030/08/31
41014.1 2022/03/29 – 2031/03/28
16519.0 2022/08/27 – 2031/08/26
74018.4 2023/03/31 - 2032/03/30
75018.2 2023/04/30 - 2032/04/29
8018.4 2023/05/02 - 2032/05/01
4018.4 2023/05/05 - 2032/05/04
8018.4 2023/05/08 - 2032/05/07
20018.4 2023/05/10 - 2032/05/09
1519.7 2023/05/13 - 2032/05/12
24027.5 2023/06/30 - 2032/06/29
6023.3 2023/08/02 - 2032/08/01
9,180
December 31, 2021
Number of
options ’000		Exercise price*
US$
per share		Exercise period
4,0540.5 2019/12/25 – 2027/12/25
1,8491.0 2019/07/01 – 2028/08/29
3821.0 2019/12/31 – 2028/12/30
1,8221.5 2020/07/02 – 2029/07/01
33211.5 2020/11/29 – 2029/11/28
9011.5 2021/06/05 – 2030/06/04
38516.3 2021/09/01 – 2030/08/31
2013.6 2021/11/19 – 2030/11/18
43014.1 2022/03/29 – 2031/03/28
16519.0 2022/08/27 – 2031/08/26
9,529
*The exercise price of the share options is subject to adjustment in the case of rights or bonus issues, or other similar changes in the Company’s share capital. Pursuant to certain listing rules of the Hong Kong Stock Exchange to which members of the Genscript Group are subject to, the Company adjusted the exercise price of options granted during November 29, 2019 through December 9, 2019 to $11.50 per share. Concurrent with this adjustment, the Company agreed to pay each employee holding affected share options an amount in cash representing the difference between the adjusted exercise price over the original exercise price upon exercising the share options.
Summary of Fair Value of Equity Settled Share Options Granted The following table lists the inputs to the model used:
202320222021
Dividend yield (%)— — — 
Expected volatility (%)66.1 %
73.0% -87.1%
73.2% - 76.4%
Risk-free interest rate (%)
3.40% - 4.84%
0.52% - 3.11%
0.03%- 1.72%
Expected life of options (year)101010